FOLD Q1 2024 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$110M+28.0% YoY

Gross Profit

$97M87.7% margin

Operating Income

-$28M-25.1% margin

Net Income

-$48M-43.9% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

-4.1%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$32M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$722M

Total Liabilities

$591M

Stockholders' Equity

$131M

Cash & Equivalents

$210M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$110M	$86M	+28.0%
Gross Profit	$97M	$79M	+22.1%
Operating Income	-$28M	-$38M	+26.3%
Net Income	-$48M	-$53M	+8.5%

Geographic Segments

Non-US

$73M66%

UNITED STATES

$37M34%